Intervention: Aldesleukin (Interleukin-2) BMS-936558 (Nivolumab) IL-2 (Interleukin-2) Interleukin-2 () Ipilimumab () Nivolumab (Opdivo) Proleukin (Interleukin-2) Yervoy (Ipilimumab) Intervention: BMS-936558 (Nivolumab) Nivolumab (Opdivo) Tavo-EP ()Ī Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma University of Pittsburgh School of Medicine - PhD.Lithuanian University of Health Sciences - MD.University of Pittsburgh Medical Center - Internal Medicine.University of Pittsburgh Medical Center - Hematology and Oncology.Tarhini’s clinical interests include melanoma (cutaneous, uveal and mucosal) and other skin cancers. Lee Moffitt Cancer Center and Research Institute Top Publication Award. He is recipient of the University of Pittsburgh Cancer Institute Junior Scholar Award in Clinical Research, the Easten Cooperative Oncology Group Research and Education Foundation Young Investigator Award and the H. He serves as a chair/co-chair on several NCI cooperative group trials, including U.S. His original work on immunotherapy of melanoma and biomarkers of disease prognosis and therapeutic benefit has been published in high-impact, peer-reviewed journals and presented at leading national/international meetings. Tarhini has led multiple clinical trials and biomarker studies funded through the NIH and other mechanisms in the field of ImmunoOncology and has investigated the role of promising biomarkers in relation to disease risk and clinical benefits of immunotherapy in the melanoma adjuvant, neoadjuvant, and advanced disease settings. While at the Cleveland Clinic, he also was Professor of Medicine at Case Western Reserve University and served as the principal investigator of the ETCTN grant at Case Comprehensive Cancer Center. Tarhini then joined the Cleveland Clinic in Cleveland, OH as Director of the Melanoma and Skin Cancer Program and Director of the Center for ImmunoOncology Research. Tarhini joined the faculty of the University of Pittsburgh School of Medicine at the rank of Assistant Professor, was promoted to Associate Professor and eventually achieved tenure. Tarhini completed an Internal Medicine Residency and a Hematology and Oncology Fellowship at the University of Pittsburgh Medical Center. He also obtained a Master of Science in Clinical Research from UPSOM and Bachelor of Science from the American University of Beirut. Dr. Tarhini obtained his MD from the Lithuanian University of Health Sciences (LSMU) and his PhD in Clinical and Translational Science from the University of Pittsburgh School of Medicine (UPSOM). Dr Tarhini also serves as Chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN) and Chair, ORIEN ImmunoOncology Research Subcommittee. He is Professor of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Tarhini also serves as the Director of Cutaneous Clinical and Translational Research and leader of the Neoadjuvant and Adjuvant Translational Science Program. Tarhini is a Tenured Senior Member in the Moffitt Cancer Center and Research Institute Departments of Cutaneous Oncology and Immunology. Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Skin Cancer (Nonmelanoma), Squamous Cell CarcinomaĪhmad Tarhini, MD, PhD is an internationally recognized physician and leading researcher in Melanoma, Skin Cancers and Immuno-Oncology.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |